What diseases is fostatinib/fotantinib used to treat?

Fostamatinib is an oral small molecule tyrosine kinase inhibitor mainly used in the treatment of immune thrombocytopenia (ITP) in adults. ITP is an autoimmune disease in which the patient's immune system abnormally recognizes and attacks platelets, resulting in a decrease in platelet count and an increased risk of spontaneous bleeding and bruising. Traditional treatments, such as glucocorticoids, intravenous immune globulin, or splenectomy surgery, may have limited efficacy or significant side effects in some patients. Fotantinib provides a new oral treatment option and brings hope to patients with chronic or refractory ITP.

Fotantinib blocks immune-mediated platelet destruction by inhibiting theSYK (Spleen Tyrosine Kinase) signaling pathway and helps the platelet count return to a safe level. This mechanism of action makes it different from traditional immunosuppression or hormone therapy, and the oral administration of the drug is suitable for long-term maintenance treatment, which significantly improves the convenience of patients' lives. Patients still need to regularly monitor blood pressure, liver function and platelet levels while taking the medication to ensure safety and efficacy. Particularly in patients who have had an inadequate response to conventional therapies, fotantinib can stabilize platelet levels and reduce the risk of bleeding.

In addition, fotantinib has shown good tolerance in international clinical practice. The vast majority of patients can tolerate conventional dose treatment and control mild to moderate side effects through dose adjustment or auxiliary management during use. The emergence of this oral small molecule targeted drug not only enriches the treatment options for ITP, but also changes the long-term management of patients, making the control of chronic diseases more flexible and sustainable, and providing patients with a safer, more convenient and reliable long-term management approach.

Overall, the advent of fotantinib provides innovative and effective treatment options for patients with refractoryITP, while improving patients' daily quality of life and disease management experience.

Reference materials:https://go.drugbank.com/drugs/DB12010